New York, June 9, 2026, 17:03 EDT
- Alignment Healthcare closed at $19.20, up about 25%, after its Goldman Sachs healthcare conference appearance.
- The move stood out against modest gains in managed-care peers and a weaker Nasdaq.
- Investors focused on stable utilization, growth in Medicare Advantage membership and the company’s raised 2026 outlook.
Alignment Healthcare shares surged on Tuesday, closing 25.1% higher at $19.20, after investors parsed the Medicare Advantage company’s presentation at Goldman Sachs’ global healthcare conference and recent operating updates. The stock traded as high as $19.62 after opening at $15.24, with volume topping 16 million shares.
The rally mattered because Alignment has been trying to show that fast membership growth can come with better margins, not just higher medical costs. Medicare Advantage, the private-plan version of U.S. Medicare, has been under pressure across the industry as insurers face tighter government payments and higher care use by seniors.
A transcript summary of the Goldman Sachs session said Alignment’s data-driven care model, disciplined expansion and stable utilization trends were supporting its financial outlook. Utilization is the rate at which members use medical care; when it rises faster than expected, insurers can see profits squeezed.
Alignment’s latest quarterly report gives investors the hard numbers behind that argument. The company said first-quarter revenue rose 33.3% to $1.24 billion, Medicare Advantage membership increased 30.9% to about 284,800 members, and adjusted EBITDA rose 87.6% to $37.9 million. Adjusted EBITDA is profit before interest, taxes, depreciation, amortization and some other costs, a common gauge of operating performance.
“Our first-quarter performance demonstrates that Alignment continues to grow with discipline,” founder and Chief Executive John Kao said when the company reported results in late April. Kao said the company expanded profitability through sales, clinical operations and cost management, “even as the Medicare Advantage environment continues to change.” Alignment Healthcare, Inc.
The company also raised the midpoint of its 2026 guidance across membership, revenue, adjusted gross profit and adjusted EBITDA. For 2026, it forecast revenue of $5.16 billion to $5.21 billion and adjusted EBITDA of $138 million to $163 million.
The move was far larger than the broader managed-care tape. UnitedHealth, Humana and Centene rose about 1.5%, 1.9% and 1.8%, respectively, while the iShares U.S. Healthcare Providers ETF gained about 1.9%. That suggests Alignment’s jump was tied more to company-specific enthusiasm than a simple sector trade.
The broader market was less helpful. The Nasdaq Composite fell about 1% on Tuesday as technology shares weakened, while the S&P 500 slipped 0.3%; healthcare and other defensive groups fared better as investors rotated away from parts of the AI trade.
There was also routine governance news after the close. A filing showed Alignment shareholders elected directors Jody Bilney, David Hodgson and Jacqueline Kosecoff to terms ending at the 2029 annual meeting, ratified Deloitte & Touche as auditor for 2026 and approved executive compensation on an advisory basis.
But the risk case has not gone away. Alignment itself warned that results could be hurt by weaker member growth, delays in entering new markets, lower Medicare Advantage funding, changes in regulation, weaker plan quality ratings, provider-relationship problems or labor-cost pressure. A fast stock move can also reset expectations quickly; if medical costs rise or 2026 guidance proves too high, Tuesday’s gain leaves less room for error.
